

Amphastar Pharmaceuticals, Inc.
Form 3
June 24, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| | | | | | |
|--|---|--|--|---|---|
| <p>1. Name and Address of Reporting Person *</p> <p>Â Purchase Marilyn J.</p> <p>(Last) (First) (Middle)</p> <p>C/O AMPHASTAR PHARMACEUTICALS, INC.,Â 11570 6TH STREET</p> <p>(Street)</p> <p>RANCHO CUCAMONGA,Â CAÂ 91730</p> <p>(City) (State) (Zip)</p> | <p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>06/24/2014</p> | <p>3. Issuer Name and Ticker or Trading Symbol</p> <p>Amphastar Pharmaceuticals, Inc. [AMPH]</p> | <p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p>___ Director ___ 10% Owner <input checked="" type="checkbox"/> Officer ___ Other (give title below) (specify below) Corp. Exec. VP of Operations</p> | <p>5. If Amendment, Date Original Filed(Month/Day/Year)</p> | <p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p><input checked="" type="checkbox"/> Form filed by One Reporting Person ___ Form filed by More than One Reporting Person</p> |
|--|---|--|--|---|---|

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|------------------------------------|--|---|--|
| Common Stock | 16,859 ⁽¹⁾ | D | Â |
| Common Stock | 2,757 ⁽²⁾ | D | Â |
| Common Stock | 11,437 ⁽³⁾ | D | Â |
| Common Stock | 17,605 ⁽⁴⁾ | D | Â |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 3

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---|--|--------------------|--|----------------------------------|--|--|---|
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | |
| Stock Option (Right to Buy) | Â <u>(5)</u> | 07/29/2014 | Common Stock | 15,000 | \$ 14.8 | D | Â |
| Stock Option (Right to Buy) | Â <u>(5)</u> | 05/15/2015 | Common Stock | 28,000 | \$ 14.8 | D | Â |
| Stock Option (Right to Buy) | Â <u>(5)</u> | 05/10/2016 | Common Stock | 15,000 | \$ 20 | D | Â |
| Stock Option (Right to Buy) | Â <u>(5)</u> | 12/03/2017 | Common Stock | 25,000 | \$ 31.02 | D | Â |
| Stock Option (Right to Buy) | Â <u>(5)</u> | 08/18/2018 | Common Stock | 25,000 | \$ 35.32 | D | Â |
| Stock Option (Right to Buy) | Â <u>(6)</u> | 08/02/2019 | Common Stock | 25,000 | \$ 20.26 | D | Â |
| Stock Option (Right to Buy) | Â <u>(7)</u> | 09/28/2020 | Common Stock | 30,000 | \$ 11.79 | D | Â |
| Stock Option (Right to Buy) | Â <u>(8)</u> | 10/03/2021 | Common Stock | 15,789 | \$ 15.23 | D | Â |
| Stock Option (Right to Buy) | Â <u>(9)</u> | 07/13/2022 | Common Stock | 47,877 | \$ 10.46 | D | Â |
| Stock Option (Right to Buy) | Â <u>(10)</u> | 09/28/2022 | Common Stock | 8,315 | \$ 10.48 | D | Â |
| Stock Option (Right to Buy) | Â <u>(11)</u> | 07/05/2023 | Common Stock | 32,081 | \$ 10.93 | D | Â |
| Stock Option (Right to Buy) | Â <u>(12)</u> | 03/27/2024 | Common Stock | 25,445 | \$ 14.4 | D | Â |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|--------------------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Purchase Marilyn J. C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730 | Â | Â | Â Corp. Exec. VP of Operations | Â |

Signatures

/s/Marilyn J. Purchase, by Power of
Attorney

06/24/2014

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This includes 16,044 shares held by the Purchase Family Trust (the "Trust"). The reporting person and her husband are the sole co-trustees of the Trust, and they share voting and investment power.

This represents the remaining amount of deferred stock units that were granted on 10/3/2011. The original amount was 5,515. This vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (2) This represents deferred stock units that were granted on 7/5/2013 and vest over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (3) This represents deferred stock units that were granted on 3/27/2014 and vest over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (4) This option is fully vested and exercisable.

This option was granted on 8/2/2009 and vests over 5 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (5) This option was granted on 9/28/2010 and vests over 5 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (6) This option was granted on 10/3/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (7) This option was granted on 7/13/2012 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (8) This option was granted on 9/28/2012 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (9) This option was granted on 7/5/2013 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (10) This option was granted on 3/27/2014 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (11) This option was granted on 7/5/2013 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (12) This option was granted on 3/27/2014 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.